



# Zanthoxylum acanthopodium DC (Andaliman): From Traditional Medicine to Modern Phytotherapy: A Review of Phytochemistry, Bioactivities, and Pharmaceutical Development

Jatla Murali Prakash<sup>1</sup>, Dampanaboina Durga Prasad<sup>1</sup>, Deepti Kolli<sup>1\*</sup>, Naresh Mameda<sup>1,2</sup>

<sup>1</sup> Department of Chemistry, Koneru Lakshmaiah Education Foundation, Greenfields, Vaddeswaram, Guntur-522302, Andhra Pradesh, India.

<sup>2</sup> Advanced Institute of Water Industry, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu 41566, Republic of Korea

\*Corresponding Author: Deepti Kolli, Department of Chemistry, Koneru Lakshmaiah Education Foundation, Greenfields, Vaddeswaram, Guntur-522302, Andhra Pradesh, India, Email: atluri.deepti1984@gmail.com

## Abstract

*Zanthoxylum acanthopodium* DC (Andaliman), a spice-bearing shrub native to North Sumatra, Indonesia, possesses a long history of traditional culinary and medicinal use. Its diverse phytochemical profile, including terpenoids, alkaloids, flavonoids, glycosides, tannins, and saponins, forms the basis of its therapeutic potential. This review systematically compiles and analyzes *in vitro* and *in vivo* evidence for its broad-spectrum pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, cardioprotective, hepatoprotective, nephroprotective, and wound-healing effects. The review emphasizes the correlation between solvent choice and bioactivity, the functions of key active compounds (e.g., limonene, quercetin, and fargesin), and elucidated therapeutic mechanisms. This work identifies critical research gaps in pharmacokinetics, toxicity, and formulation, proposing a strategic roadmap for translational research. This review provides a consolidated scientific foundation to guide the future development of *Andaliman* as a modern therapeutic agent and functional food ingredient.

**Keywords:** *Zanthoxylum acanthopodium*; Ethnopharmacology; phytochemistry; pharmacokinetics.

## 1. Introduction

Southeast Asia, particularly Indonesia, is recognized as a global hotspot of medicinal plant biodiversity, with thousands of species documented for therapeutic applications. The region's deep-rooted tradition of herbal medicine is vital in primary healthcare, yet despite this rich ethnobotanical heritage, the pharmacological efficacy and mechanisms of action remain underexplored (Elfahmi et al. ; Lubis et al. 2022; De Padua et al. 1999; Sangat et al. 2000; RAHMAWATY et al. 2019; Rapoliene et al. 2023). Among these promising species is *Zanthoxylum acanthopodium* DC, or Andaliman, a spice-bearing shrub of the Rutaceae family found in the highland regions of North Sumatra, Indonesia. Renowned for its distinctive citrus-pepper aroma, Andaliman is a culinary staple (DM R et al. 2021) and is prominent in traditional Indonesian and Indian medicinal systems (Begum et al. 2018). Various plant parts, including the bark, roots, and seeds, have been historically employed to treat ailments such as cholera, digestive disorders, skin infections, and fever (Panjaitan et al. 2021; Bhattacharya et al. 2017; Devi et al. 2015; Sonangda et al. 2019; Syari et al. 2019). Phytochemical analyses have confirmed that *Z. acanthopodium* is rich in diverse secondary metabolites, including alkaloids, terpenoids, flavonoids, glycosides, tannins, and essential oils (Xuliang et al. 2022; SARAGIH et al. 2019). Notably, compounds such as citronellal and limonene are associated with immunomodulatory and antimicrobial properties. Pharmacological studies have validated its antioxidant, anti-inflammatory, antibacterial, antifungal, anticancer, and cardioprotective effects (Gea et al. 2022; Amelia et al. 2020; Ompusunggu et al. 2021).

Despite its rich ethnobotanical history and pharmacological profile, the translational development of *Zanthoxylum acanthopodium* remains constrained. While other species within the *Zanthoxylum* genus have been extensively reviewed, *Zanthoxylum acanthopodium* is underrepresented and critically lacks a synthesis that bridges its documented bioactivities with the significant hurdles to clinical application (Wijaya et al. 2019; Syahputra et al. 2023; Hutapea et al. 2024). Therefore, the primary objective of this review is twofold: first, to systematically consolidate and critically evaluate current knowledge on the plant's ethnobotany, phytochemistry, and diverse pharmacological activities, and second, to provide the first in-depth analysis of the significant transitional gaps, namely, the lack of pharmacokinetic (ADME) and comprehensive toxicological data. By identifying these crucial research gaps, this review proposes a strategic, multidisciplinary research road map to serve as a definitive foundation to guide the development of *Z. acanthopodium* as a standardized, evidence-based phytopharmaceutical and functional food ingredient.

## 2. Literature search strategy

A systematic literature search was conducted across multiple electronic databases (ScienceDirect, PubMed, Web of Science, Google Scholar, and Baidu Scholar) for publications from January 2000 to December 2024. The search

utilized the keywords: “*Zanthoxylum acanthopodium*,” “Andaliman,” “phytochemistry,” “traditional use,” “bioactivity,” and “pharmacology.” The primary search was supplemented by screening institutional repositories, relevant M.Sc. and Ph.D. dissertations, and reference lists of key articles. Inclusion was limited to peer-reviewed research articles and conference proceedings that reported traditional uses, chemical profiling, or experimental evidence (in vitro/in vivo) of pharmacological activity. Duplicate entries and non-English publications were excluded.

### 3. Botanical and ethnomedicinal overview

*Zanthoxylum acanthopodium* DC is a deciduous shrub or small tree from the Rutaceae family, typically reaching 2-3 meters in height. (Sonangda et al. 2019) Its key features include compound pinnate leaves with 5-7 pairs of ovate-lanceolate leaflets, sharp spines on its branches, and small greenish-yellow flowers arranged in panicles (Fig. 1) (RAHMAWATY et al. 2019; Sonangda et al. 2019). The spherical fruits (4-5 mm) transition from reddish-brown to black upon ripening and contain essential oils responsible for the plant’s characteristic citrus-like aroma (B Siregar. 2003). Native to the tropical and subtropical highlands of North Sumatra, *Z. acanthopodium* thrives in well-drained, moist soils and demonstrates considerable ecological resilience, making it suitable for wild harvesting and cultivation (Siahaan et al. 2019). The plant holds a significant place in traditional Indonesian and Ayurvedic medicine. The roots are employed to treat gastrointestinal disorders and inflammation; the bark and seeds are used as tonics for fever, cholera, and dyspepsia; and crushed fruits are topically applied for skin ailments. Its essential oils are used as insect repellents and culinary condiments. This extensive ethnomedicinal history suggests that the fruit, bark, and root are rich reservoirs of bioactive compounds, warranting the detailed pharmacological validation explored in this review. *Zanthoxylum acanthopodium* has a long and varied history of ethnomedicinal use across Southeast Asia, particularly in North Sumatra, where it serves both a culinary and therapeutic role. Various plant parts, including the roots, bark, seeds, and fruits, are traditionally used to treat numerous conditions. Table 1 comprehensively summarizes these traditional applications, the plant parts used, preparation methods, and the associated health benefits spanning gastrointestinal, inflammatory, antimicrobial, and dermatological domains (Begum et al. 2018; Amelia et al. 2020; Suryanto et al. 2004; Farida et al. 2021; Susanti et al. 2020; Anggraeni. 2020; Majumder et al. 2014; Datta et al. 2013). Beyond its specific therapeutic application, the plant’s role in food is notable. In North Sumatran cuisine, the fruits and seeds are a key spice, imparting a pungent, tingling sensation to traditional condiments and meat dishes. This culinary use also extends to food preservation, a practice supported by the known antimicrobial action of essential oils (Frederick et al. 2021). These diverse applications underscore the dual cultural and therapeutic significance of *Z. acanthopodium* and provide a strong rationale for its pharmacological investigation and potential development as a modern functional food and phytomedicine.

**Table 1.** Traditional uses of *Zanthoxylum acanthopodium*


Traditional application	Plant part used	Use/ application	Health or cultural benefit	Ref
Gastrointestinal health	Roots, Bark	Decoctions or tonics	Indigestion, diarrhea, cramps, stomach discomfort	Farida et al., 2021
Oral care	Bark	Chewing bark	Toothache, antibacterial hygiene	Susanti et al.,
Culinary use	Fruits, Seeds	Spice, condiment	Pungent taste; used in food preservation	Anggraeni et al., 2020
Respiratory relief	Essential oil, Bark	Inhalation, tonic	Cough, colds, bronchial irritation	Majumder et al., 2014
Antimicrobial/ Antifungal	Essential oil, Bark, Fruits	Topical or oral application	Skin infections, wound abscesses	Amelia et al., Majumder et al., 2014
Inflammatory conditions	Roots, Bark	Decoctions	Inflammation, pain	Datta et al., 2013
Anti-parasitic	Fruits, Seeds	Ingestion	Roundworms, intestinal parasites	Shylla et al., 2022
Insect repellency	Essential oil	Topical, fumigation	Mosquito and insect repellent	He et al., 2018
Dermatological use	Bark, Essential oil	Topical application	Skin diseases, leprosy, abscesses	Begum et al., 2018
Anticancer	Fruits, Bark	Empirical use	Cancer remedy (modern in vitro evidence supports activity)	Bhattacharya et al., 2017



**Fig. 1.** Key botanical features of *Zanthoxylum acanthopodium* DC. The figure displays a composite photograph of the plant alongside a schematic summary of its primary morphological characteristics.

#### 4. Phytochemical profile and analysis

*Zanthoxylum acanthopodium* possesses various secondary metabolites that contribute to its pharmacological activities. Major classes identified in the plant include alkaloids, flavonoids, phenolics, terpenoids, saponins, tannins, coumarins, steroids, and glycosides. (Megawati et al. 2023) The efficiency of extracting these compounds is highly dependent on solvent polarity, a critical factor for isolating bioactive fractions. As the preliminary phytochemical screening of fruit extracts demonstrates (Fig. 2), polar solvents like methanol effectively extract a broad spectrum of compounds (Muzafri et al. 2018). In contrast, non-polar solvents such as hexane are more selective for compounds like steroids/triterpenoids, while failing to extract key classes like alkaloids and anthraquinone glycosides. This solvent-dependent profile is fundamental for designing extraction protocols tailored to specific pharmacological investigations (Muzafri et al. 2018).



**Fig. 2.** Heat map of the phytochemical profile of *Zanthoxylum acanthopodium* fruit extracts. Major phytochemical classes' presence (green) and absence (grey) were assessed across four extraction solvents. The diagram on the y-axis indicates hierarchical clustering of phytochemical diversity based on the solvent extraction pattern.

Characterization of these phytochemicals is typically achieved through a combination of extraction and advanced analytical techniques. Steam distillation followed by Gas Chromatography-Mass Spectrometry (GC-MS) is standard for volatile components, particularly essential oils. This approach has been crucial for identifying bioactive monoterpenes such as citral and limonene, which are responsible for their antibacterial properties (Panjaitan et al. 2021). For non-volatile constituents (alkaloids and flavonoids), Soxhlet extraction using polar and semi-polar solvents (e.g., methanol, ethanol, ethyl acetate) is commonly paired with Liquid Chromatography-Mass Spectrometry (LC-MS) (Pradeep et al. 2014). The high resolution of LC-MS enables detailed profiling even at low concentrations (Sibero et al. 2020). The complementary use of GC-MS and LC-MS enables comprehensive chemical characterization, facilitating the correlation of phytochemical profiles with observed pharmacological effects.

#### 6. Pharmacological properties

*Zanthoxylum acanthopodium* exhibits a broad spectrum of pharmacological effects that have garnered growing scientific attention (Wen et al. 2024). Bioactivity studies confirm its potential in modulating oxidative stress, inflammation, microbial infections, cancer progression, and cardiovascular dysfunction. These therapeutic effects are primarily attributed to its diverse secondary metabolites, including flavonoids, terpenoids, alkaloids, and

essential oils. The following subsections summarize key pharmacological activities, supported by *in vitro* and *in vivo* studies, highlighting bioactive constituents, experimental models, assay outcomes, and mechanisms of action.

### 6.1 Antioxidant activity

The antioxidant potential of *Z. acanthopodium* has been extensively validated through multiple chemical assays. For example, methanol extracts of the fruit, rich in flavonoids and phenolics such as quercetin and neohesperidin, exhibited notable free radical scavenging activity in the CUPRAC assay ( $IC_{50} = 86.58 \mu\text{g/mL}$ ). In contrast, the plant's essential oil, containing high levels of D-limonene and geranyl acetate, displayed more potent activity in the DPPH assay ( $IC_{50} = 28.37 \mu\text{g/mL}$ ). Such variations are expected, as different antioxidant assays (CUPRAC, DPPH, FRAP, and ABTS) rely on distinct redox mechanisms and are sensitive to differences in radical species, solvent polarity, and incubation periods (Rahmi et al. 2023; Assyfa et al. 2024). Despite these assay-sensitive differences, the collective evidence suggests that *Z. acanthopodium* is a potent source of natural antioxidants. This capacity is fundamental to many other therapeutic effects and supports its potential applications in preventing and managing oxidative stress-related disorders.

### 6.2 Anti-inflammatory activity

The anti-inflammatory potential of *Z. acanthopodium* has been validated through nitric oxide (NO) inhibition assays in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Bark extracts obtained using petroleum ether and ethyl acetate strongly suppressed NO production (by 70% at  $40 \mu\text{g/mL}$ ), significantly outperformed n-butanol extracts. Bioassay-guided fractionation of the petroleum ether extract via high-performance counter-current chromatography (HPLC) isolated the active lignans, fargesin and epiudesmin. Mechanistically, these compounds significantly downregulated the expression of pro-inflammatory cytokines TNF- $\alpha$  and IL-1 $\beta$ , indicating the potent immunomodulatory potential of the extracts.


The plant's essential oils also exhibited significant anti-inflammatory properties, though activity varies with geographical origin. Oils from fruits collected in China (EOZC) showed superior efficacy ( $IC_{50} = 16 \mu\text{g/mL}$ ), comparable to the control L-NMMA ( $IC_{50} = 12.2 \mu\text{g/mL}$ ). In contrast, oil from Myanmar (EOZM) showed moderate activity ( $IC_{50} = 37 \mu\text{g/mL}$ ). This variation is likely attributed to differences in their phytochemical profiles, particularly in the relative abundance of key monoterpenes and sesquiterpenes (limonene,  $\beta$ -myrcene, and terpinen-4-ol) (Yang et al. 2022; Fan et al. 2023). These findings underscore *Z. acanthopodium* as a promising source of natural anti-inflammatory agents, with bioactivity contribution from its non-volatile lignans and essential oil components.

### 6.3 Antimicrobial activity

*Z. acanthopodium* demonstrates substantial antimicrobial activity, with compounds derived from the plant's extracts, essential oils, and even its resident microbiome capable of combating various bacterial and fungal pathogens (Julistiono et al. 2018). The plant's activity is frequently selective, with multiple preparations demonstrating potency against distinct classes of microbes. The following subsections provide a more detailed account of these discoveries.

#### 6.3.1. Antifungal activity

The antifungal potential of *Z. acanthopodium* has been demonstrated against various fungi and dermatophytes. Among solvent-based preparations, the petroleum ether (PE) extract exhibits notable efficacy against pathogens like *C. albicans* and *C. krusei*, while other extracts showed more moderate activity (Devi et al. 2015). The plant essential oils, however, display particularly potent and geographically variable activity (Fig. 3). Essential oil sourced from China (EOZC) is highly effective against a broad spectrum of dermatophytes, with the most vigorous activity observed against *E. floccosum* ( $MIC_{90} = 26.3 \mu\text{g/mL}$ ). In contrast, oil from Myanmar (EOZM) is consistently less potent across the same fungal strains. The difference in potency is linked to their distinct chemotypes; superior activity of EOZC is attributed to higher levels of limonene and  $\beta$ -myrcene, which disrupt fungal membranes and inhibit fungal spore germination. Conversely, the more moderate activity of EOZMs is likely due to dominant compounds, terpinen-4-ol and  $\gamma$ -terpinene, which interfere with fungal membrane permeability and enzymatic processes. (Fan et al. 2023)



**Fig. 3.** Minimum Inhibitory Concentration (MIC) values of *Zanthoxylum acanthopodium* extracts against fungal strains. Lower MIC values (in blue) indicate stronger antifungal activity. EOZC (China) exhibits potent efficacy, particularly against *E. floccosum*, compared to EOZM (Myanmar) and solvent extracts. "--" denotes missing or unreported MIC values.

### 6.3.2. Antibacterial activity

The antibacterial potential of *Z. acanthopodium* has been demonstrated against a range of clinically relevant pathogens, with bioactive compounds originating from both the plant itself and its resident endophytic bacteria (Table 2). Notably, endophytic bacteria isolated from the plant have shown significant promise. (Muzafri et al. 2022) For instance, several root-derived endophytes exhibited vigorous, selective activity against *B. subtilis*, with Minimum Inhibitory Concentration (MIC) values confirming their efficacy. (Rizqoh et al. 2024) Methanolic fruit extract showed limited activity against marine pathogens (e.g., *Tenacibaculum maritimum* and *Vibrio*) but exhibited cytotoxicity toward murine P388 leukemia cells (IC<sub>50</sub> = 19.14 µg/mL), indicating potential anticancer relevance (Sibero et al. 2020).

Solvent-based extracts of various plant parts also display significant antibacterial efficacy. The extracts obtained with polar solvents (ethanol and ethyl acetate) consistently show the most potent and broad-spectrum activity against both gram-positive (*B. subtilis*) and gram-negative (*S. typhi*), attributed to a rich profile of alkaloids, steroids, tannins, and saponins (Sitanggang et al. 2019; Sihombing et al. 2019; Ira et al. 2022). Notably, essential oils derived from the stems (ZACS) display high selectivity against gram-negative bacteria like *Escherichia coli* (MIC = 128 µg/mL), an effect attributed to their high content of monoterpenes and sesquiterpenes, which are known to disrupt bacterial outer membranes more effectively than in Gram-positive bacteria (Diep et al. 2023).

**Table 2.** Antibacterial activity of *Zanthoxylum acanthopodium* extracts against selected bacterial strains using various solvents and bioassays.

Plant Part	Extract Source	Target Bacteria	Methods	Ref
Root	Methanolic	<i>Bacillus subtilis</i>	Kirby-Bauer disc diffusion, MIC	Rizqoh et al., 2024
Root	Ethyl acetate	<i>Bacillus subtilis</i>	Antagonist test, disc diffusion	
Stem	Ethyl acetate	<i>Bacillus subtilis</i>	Antagonist test, MIC	
Fruit	Methanolic	<i>Tenacibaculum maritimum</i> ; <i>Vibrio alginolyticus</i> ; <i>V. anguillarum</i> , <i>V. Harveyi</i> ; Murine P388 leukemia cells.	Kirby-Bauer disc diffusion, XTT cytotoxicity assay	Sibero et al., 2020
Fruit	Ethyl acetate	<i>Escherichia coli</i>	Agar diffusion, MIC	Sitanggang et al., 2019
Fruit	Ethanol	<i>Bacillus subtilis</i> ; <i>Salmonella typhi</i>	Disc diffusion method	Sihombing et al., 2019
Fruit	Ethanol	<i>Staphylococcus aureus</i> ; <i>Staphylococcus epidermidis</i>	MIC, Disc diffusion	Ira et al., 2022

Fruit	Various solvents (Ethyl acetate, Methanol, Hexane, Aqueous)	<i>Escherichia coli</i>	Disc diffusion	Muzafri et al., 2022
-------	---	-------------------------	----------------	----------------------

### 6.3.3. Activity of purified compounds


Beyond crude extracts and oils, bioactivity-guided isolation has identified potent purified compounds. Two novel antimicrobial compounds isolated from the fruit, MKC-1 and MKC-2, exhibited broad-spectrum activity against bacteria and fungi (Table 3). Notably, MKC-2 demonstrated superior potency, with larger inhibition zones and lower MIC values than MKC-1 across multiple strains. The high, broad-spectrum efficacy of MKC-2 establishes it as a promising lead compound for natural antimicrobial drug development (Thu et al.).

The evidence suggests that *Z. acanthopodium* exhibits significant potential as an antimicrobial agent. Its activity is diverse, demonstrating antifungal properties against dermatophytes and antibacterial efficacy against Gram-negative bacteria. The discovery of potent, broad-spectrum purified compounds like MKC-2, alongside the observed activity in its essential oils and even its associated microbiome, further enhances this plant's promise as a source for novel antimicrobial agents to combat drug-resistant bacteria and fungi.

### 6.4. Antiviral and Larvicidal Activities

Essential oils extracted from *Z. acanthopodium* fruits collected in China (EOZC) and Myanmar (EOZM) have shown promising antiviral properties, particularly against the dengue virus (DENV) and Zika virus (ZIKV). The plant's potential for a dual-pronged approach, targeting both the virus and its mosquito vector, makes it a subject of considerable interest. The essential oil from Myanmar (EOZM) exhibited superior antiviral efficacy compared to the oil from China (EOZC) (Fig. 4). Against DENV, EOZM is highly potent ( $IC_{50} = 13 \mu\text{g/mL}$ ) and exhibits an affordable safety profile, indicated by a high selectivity Index ( $SI = 14$ ). This potency surpasses that of the standard antiviral reference compound (NITD008). While also active against ZIKV, its efficacy is more moderate ( $IC_{50} = 94 \mu\text{g/mL}$ ). In contrast, EOZC is significantly less effective, showing only moderate antiviral activity against DENV ( $IC_{50} = 184.86 \mu\text{g/mL}$ ;  $SI = 4.35$ ) and no inhibition of ZIKV. This difference in potency is likely attributed to their distinct phytochemical profiles, with the superior activity of EOZM linked to its higher abundance of limonene and  $\beta$ -myrcene, which are known to interfere with viral envelope integrity and host-virus fusion mechanisms (Yang et al. 2022).

Beyond its direct antiviral action, *Z. acanthopodium* essential oils also possess larvicidal properties. Prior studies have reported larvicidal activity of its oils against the larvae of mosquito vectors, further supporting their potential role in dengue vector control programs. This complementary activity, like the oil's rich monoterpene content, supports a potential dual-application strategy, inhibiting viral replication while simultaneously controlling the vector population.



**Fig. 4.** Comparative  $IC_{50}$ ,  $CC_{50}$ , and SI values of *Zanthoxylum acanthopodium*-derived antiviral agents against DENV and ZIKV.  $IC_{50}$  and  $CC_{50}$  are expressed in  $\mu\text{g/mL}$ , while SI is dimensionless. Lower  $IC_{50}$  and higher SI values indicate superior antiviral efficacy.

Further strengthening its role in vector control, the essential oil of *Zanthoxylum acanthopodium* has demonstrated potent larvicidal effects against two key malaria vectors, including *Anopheles anthropophagus* and *Anopheles sinensis*. In WHO-standard bioassays, the oil induced dose-dependent larval mortality, with 24-hour  $LC_{50}$  values of 36.00 mg/L and 49.02 mg/L. GC-MS analysis of the oil identified estragole (15.46%) and eucalyptol (10.94%) as primary active

components; both compounds exhibited comparable toxicity against larvae (He et al. 2018). These results establish the essential oil as a sustainable botanical alternative to synthetic pesticides for use in malaria-endemic regions.

**Table 3.** Comparative IC<sub>50</sub> and MIC values of *Zanthoxylum acanthopodium* essential oils and purified compounds against bacterial and fungal strains, with classification of antimicrobial efficacy.

Sample	Microbial Strain	IC <sub>50</sub> (µg/mL)	MIC (µg/mL)	Activity classification	Ref
ZACL (Leaves)	<i>Staphylococcus aureus</i>	>512	512	Minimal inhibitory effect	Diep et al., 202
	<i>Bacillus subtilis</i>	>512	>512	Ineffective	
	<i>Lactobacillus fermentum</i>	>512	>512	Ineffective	
	<i>Escherichia coli</i>	89.83 ± 1.15	512	Moderate efficacy	
	<i>Pseudomonas aeruginosa</i>	320.0 ± 3.56	512	Low efficacy	
	<i>Salmonella enterica</i>	>512	>512	Ineffective	
	<i>Candida albicans</i>	433.45 ± 4.29	>512	Minimal antifungal effect	
ZACS (Stems)	<i>Staphylococcus aureus</i>	>512	512	Minimal inhibitory effect	Diep et al., 202
	<i>Bacillus subtilis</i>	490.06 ± 4.82	>512	Minimal efficacy	
	<i>Lactobacillus fermentum</i>	>512	>512	Ineffective	
	<i>Escherichia coli</i>	83.06 ± 1.08	128	Moderate to high efficacy	
	<i>Pseudomonas aeruginosa</i>	291.31 ± 2.63	512	Low efficacy	
	<i>Salmonella enterica</i>	>512	>512	Ineffective	
	<i>Candida albicans</i>	192.0 ± 2.25	512	Minimal antifungal effect	
MKC-1	<i>Bacillus pumilus</i>	ND	19.4	Medium Activity	Thu et al., 2024
	<i>Bacillus subtilis</i>	ND	16.77	Medium Activity	
	<i>Candida albicans</i>	ND	17.5	Medium Activity	
	<i>Escherichia coli</i>	ND	18.72	Medium Activity	
	<i>Pseudomonas aeruginosa</i>	ND	22.4	High Activity	
	<i>Salmonella typhimurium</i>	ND	17.27	Medium Activity	
MKC-2	<i>Bacillus pumilus</i>	ND	23.2	High Activity	Thu et al., 2024
	<i>Bacillus subtilis</i>	ND	22.64	High Activity	
	<i>Candida albicans</i>	ND	22.1	High Activity	
	<i>Escherichia coli</i>	ND	22.72	High Activity	
	<i>Pseudomonas aeruginosa</i>	ND	27.5	High Activity	
	<i>Salmonella typhimurium</i>	ND	22.01	High Activity	

\*ND represents not determined.

### 6.5. Anticancer activity

*Zanthoxylum acanthopodium* extracts have shown broad-spectrum cytotoxicity against various cancer cell lines, attributed to a rich profile of secondary metabolites, including flavonoids, alkaloids, saponins, tannins, and triterpenoids (Harahap et al. 2018). These compounds disrupt cancer signalling pathways by inducing apoptosis, promoting cell cycle arrest, and inhibiting metastasis, with key findings summarized in Table 4. The anticancer effects have been documented across several major cancer types. In the breast cancer model, activity highly depends on the solvent extract. At the same time, crude ethanol extracts show only moderate cytotoxicity against MCF-7 cells (IC<sub>50</sub> = 221.31 µg/mL) (Arsita et al. 2019). Against T47D cells, fruit's ethyl acetate fraction (EAF) induces G0/G1 cell cycle arrest (IC<sub>50</sub> = 48.94 µg/mL) via cyclin D1 and p53 upregulation (D Satria et al. 2019). Similarly, the EAF displayed potent cytotoxicity against 4T1 cells (IC<sub>50</sub> = 54.48 µg/mL), likely due to its high phenolic and flavonoid content. (R Rosidah et al. 2019) Another EAF has been shown to inhibit 4T1 cell migration and induce G2/M phase arrest by suppressing key markers of metastasis like COX-2 and VEGFR-2. The ethanol extracts also showed moderate activity against HepG2 liver cancer cells (IC<sub>50</sub> = 122.65 µg/mL), with apoptosis likely driven by flavonoids and tannins. In colorectal cancer models, ethanol extracts exhibited potent activity against HCT-116 and WiDr cell lines (IC<sub>50</sub> = 94.64 and 95.61 µg/mL), RT-PCR analysis confirming that activity is driven by apoptosis via

upregulation of the pro-apoptotic Bax/Bcl-2 ratio (Tala et al. 2022; Napitupulu et al. 2022). A consistent trend observed across these studies is that ethyl acetate fractions consistently demonstrate higher cytotoxic potency than crude ethanol extracts, suggesting that the most active compounds have a semi-polar character. The ability of these extracts and their constituents to induce cell cycle arrest, modulate tumour markers, and promote apoptosis highlights *Z. acanthopodium* as a promising source of phytochemicals for anticancer drug development. Future work should focus on compound isolation, structural characterization, and *in vivo* validation to support translational potential.

**Table 4.** Cytotoxic activity of *Zanthoxylum acanthopodium* extracts and purified fractions against various cancer cell lines, including associated IC<sub>50</sub> values, primary and secondary metabolites, and experimental methods employed.

Cell Line	IC <sub>50</sub> (µg/mL)	Secondary Metabolites	Method	Ref
MCF-7	221.31	Alkaloids, triterpenoids, flavonoids, tannins, phenols, and saponins	MTT Assay	Arsita et al., 2019
T47D	48.94	Alkaloids, tannins, saponins, and flavonoids	MTT Assay, Flow Cytometry, Immunocytochemistry	Satria et al., 2019
4T1	54.48	Tannins, saponins, alkaloids, and flavonoids	MTT Assay	Rosidah et al., 2019
HepG2	122.65	Saponins, alkaloids, flavonoids, and tannins	MTT Assay	Tala et al., 2022
HCT-116	94.64	Alkaloids, Tannins, Saponins, and Flavonoids	MTT Assay, RT-PCR	Napitupulu et al., 2022
WiDr	95.61	Tannins, saponins, alkaloids, and flavonoids	MTT Assay, RT-PCR	
4T1	48.1	Tannins, Triterpenoids, Alkaloids, and Flavonoids	MTT Assay, Flow Cytometry, Wound Healing, qRT-PCR	Harahap et al., 2018

### 6.6 Cardioprotective activity

*Z. acanthopodium* exhibits promising cardioprotective effects, particularly in mitigating doxorubicin-induced cardiotoxicity, primarily driven by severe oxidative stress. This activity was validated in a preclinical Wistar rat model where doxorubicin (20 mg/kg, i.p) induced myocardial injury. Subsequent oral administration of hydroalcoholic and ethyl acetate extracts (300 mg/kg for nine days) effectively counteracted the damage. The extracts produced a marked reduction in cardiac injury biomarkers (BNP, CK-MB, cTnT), restoring them to levels comparable to groups treated with standard antioxidants such as rutin and vitamin E. These biochemical findings were corroborated by histopathological examination, which confirmed myocardial preservation via significantly reduced cellular necrosis, myocytolysis, and vascular congestion in the extract-treated groups. This potent action is attributed to the plant's rich content of antioxidant phytochemicals, including flavonoids and alkaloids, which scavenge reactive oxygen species (ROS). By preserving myocardial integrity and reducing oxidative load, *Z. acanthopodium* extracts show promise as a natural therapeutic agent for minimizing or preventing drug-induced cardiotoxicity (Dalimunthe et al. 2024; Sihotang et al. 2016).

### 6.7. Wound healing activity and tissue regeneration

*Z. acanthopodium* has emerged as a promising agent for tissue regeneration, particularly when incorporated into advanced wound dressings using modern formulation technologies. For instance, micro-colloidal Andaliman (MZA), rich in flavonoids, terpenoids, and tannins, was incorporated into bacterial cellulose (BC) to create a bioactive scaffold. In *in vivo* rat wound models, these BC-MZA composites significantly accelerated healing. The optimal formulation results in complete wound closure by Day 18, with notable improvement in bacterial clearance, re-epithelialization, and tissue remodelling. These effects are attributed to the anti-inflammatory and antioxidant properties of plants' phytochemicals, which promote wound contraction and reduce infection risk (Pasaribu et al. 2020). The plant's therapeutic potential is further highlighted in diabetic burn injury models using nano-formulated essential oils. Daily topical application of 5% nano-formulation led to significant upregulation of Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and tissue repair. Macroscopically, this enhanced neovascularization and cellular proliferation translated to ~90% wound closure by Day 14, comparable to standard commercial wound care products (Xuliang et al. 2022; Manurung et al. 2021). These studies underscore the integration of *Z. acanthopodium* into modern nanotechnology platforms, harnessing its phytochemical synergy for wound healing. This approach offers a viable pathway toward developing natural, plant-based alternatives to synthetic wound therapies.

## 7. Pharmacokinetics and Metabolism

Despite extensive research into its pharmacology, direct pharmacokinetic (PK) and ADME (absorption, distribution, metabolism, excretion) data for *Z. acanthopodium* constituents remain limited, representing a critical knowledge gap (Satria et al. 2023). Insights can, however, be drawn from related species. Major phytoconstituents, including flavonoids and alkaloids, are known to undergo extensive hepatic metabolism via cytochrome P450 (CYP450) enzymes. Specifically, studies on species like *Z. nitidum* show that alkaloids such as magnoflorine and skimmianine exhibit good oral bioavailability and sustained plasma retention in rodent models (Purba et al. 2017). This indicates alkaloid-rich fractions of *Z. acanthopodium* may share these favourable PK traits. Since its extracts are bioactive in vitro at physiologically relevant concentrations, dedicated PK investigations are essential to bridge the gap between in vitro efficacy and potential in vivo application (Panggabean et al. 2020).

A comprehensive pharmacokinetic profiling program is essential to assess its clinical viability. Key research priorities include: (i) quantitative bioavailability studies using LC-MS/MS or UPLC methods; (ii) metabolite identification and metabolic pathway mapping; (iii) pharmacokinetic-pharmacodynamic (PK-PD) modeling to correlate systemic exposure with therapeutic outcomes; and (iv) *in vitro* assays for CYP450 enzyme and drug transporter (e.g., P-glycoprotein) interactions. Elucidating these ADME properties is essential in transitioning *Z. acanthopodium* from a traditional ethnobotanical resource to a clinically validated phytopharmaceutical.

## 8. Toxicology and Safety Assessment

Toxicological evaluation is a critical prerequisite for the clinical development of *Zanthoxylum acanthopodium* phytotherapeutics. Acute toxicity studies indicate a relatively high safety threshold; methanolic fruit extracts produced no mortality at doses up to 5000 mg/kg, and the nano-formulated version demonstrated a high LD<sub>50</sub> of 9.807 g/kg in rodent models. However, subacute exposure reveals potential risks that temper this potentially acute profile. Despite high LD<sub>50</sub>, histopathological examinations have revealed dose-dependent changes in vital organs, including the liver, lungs, heart, and brain. Furthermore, subacute administration (200-1000 mg/kg over 28 days) resulted in physiological and biochemical alterations, including reduced weight gain, hematological disruptions, and clear evidence of hepatic and renal cellular damage (Situmorang, 2020; Shylla et al. 2022).

A particularly significant concern identified in subacute studies is potential reproductive toxicity. At higher doses, extracts were found to decrease sperm count and viability and to induce morphological abnormalities. This suggests that certain phytoconstituents may impair reproductive health, a finding that warrants extensive further investigation. In summary, *Z. acanthopodium* extracts exhibit low acute toxicity; these findings underscore the potential for organ-specific and reproductive risks associated with prolonged or high-dose exposure. Future studies should focus on dose optimization, extract standardization, long-term toxicity studies, and reproductive toxicology profiling to ensure safety for clinical and functional food applications.

## 9. Conclusion and Future Perspectives

While *Zanthoxylum acanthopodium* possesses a promising pharmacological profile, several critical knowledge gaps hinder its complete translation from ethnobotanical use to evidence-based phytopharmaceutical. Mechanistically, while bioactivity is established, the precise molecular targets and signalling pathways for many of its effects remain uncharacterized. From a translation perspective, a near-complete lack of pharmacokinetic (ADME) data limits any rational dose optimization or safety assessment. Furthermore, significant variability in phytochemical profiles, arising from plant origin, solvent polarity, and extraction techniques, complicates the standardization and reproducibility outcomes. Finally, the safety profile is incomplete, and comprehensive chronic and reproductive toxicity studies are needed before human clinical trials can be considered.

A strategic, multidisciplinary research roadmap is essential to address these limitations and unlock the full potential of *Z. acanthopodium*. Future work must prioritize elucidating molecular mechanisms employing biology approaches (e.g., transcriptomics, proteomics, metabolomics). This must be paired with comprehensive *in vivo* ADME studies and physiologically based pharmacokinetic (PBPK) modelling to understand the systemic fate of key constituents. To overcome the issues of variability and bioavailability, research should focus on developing advanced drug delivery systems, such as nanoemulsions and phytosomes, and establishing standardization protocols using defined phytochemical markers (e.g., limonene fragesin). The preclinical safety profile must be completed through long-term toxicology studies before proceeding to carefully designed Phase I clinical trials to assess safety, tolerability, and potential drug or herb interactions.

By systematically addressing these gaps, the scientific community can successfully transition *Z. acanthopodium* from a plant of rich ethnobotanical tradition into a source of validated next-generation phototherapeutics. Exploring its potential in novel applications, including antimicrobial wound care dressings, botanical insecticides, and synergistic dung combinations, will further solidify its place in modern medicine and environmental health.

## Acknowledgments

The authors gratefully acknowledge the support of the Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, provided. Authors like to recognize the DST through technical support from SR/PURSE/2023/196.

## References

1. Amelia, S., Lubis, N., Balatif, R., Rozi, M., Sidhi, S. (2020) Antibacterial effect of andaliman (*Zanthoxylum acanthopodium*) against contaminant in raw common carp (*Cyprinus carpio* Linnaeus). IOP Conf. Ser.: Earth Environ. Sci. 425, 012036.

2. Anggraeni, R. (2020) Uji karakteristik simplisia buah andaliman (*Zanthoxylum acanthopodium* DC.). *J. Ilm. Farm. Imelda* 3(2), 32–38.
3. Arsita, E.V., Saragih, D.E., Aldrin, K. (2019) Anticancer potential of ethanol extract of *Zanthoxylum acanthopodium* seeds against MCF-7 cells. *IOP Conf. Ser.: Earth Environ. Sci.* 293(1), 012016.
4. Assyfa, A., Dalimunthe, A., Satria, D., Muhammad, M., Mun, C.Y. (2024) Phytochemical analysis and antioxidant activity of methanol extract of *Zanthoxylum acanthopodium* fruits using CUPRAC method. *Int. J. Appl. Pharm.* 16(4), 34–37.
5. Begum, M., Lyngdoh, W., Sharma, H. (2018) Formulation and evaluation of mosquito repellent ointment prepared with the essential oil of *Zanthoxylum acanthopodium* DC. *Int. J. Green Pharm.* 12(3), 12518–527.
6. Bhattacharya, J., Aparna Lakshmi, I., Ata, S., Sarma, O.S. (2017) Evaluation of cytotoxic activity of *Zanthoxylum acanthopodium* in Dalton's lymphoma ascites cells induced cancer in mice. *Eur. J. Biomed. Pharm. Sci.* 4(10), 541–548.
7. Dalimunthe, A., Satria, D., Sitorus, P., Harahap, U., Angela, I.F.D., Waruwu, S.B. (2024) Cardioprotective effect of hydroalcoholic extract of *Zanthoxylum acanthopodium* fruits in doxorubicin-treated rats. *Pharmaceuticals* 17(3), 359.
8. Datta, S., Debarupa, D., Nilanjan, S., Prithviraj, C., Jyotirmoy, D., Amitava, G. (2013) Pharmacognostic profiling and pharmacological screening of *Zanthoxylum acanthopodium* DC—A Sub-Himalayan shrub of ethnomedicinal value. *Am. J. PharmTech Res.* 3(3), 712–720.
9. De Padua, L.S., Bunyapraphatsara, N., Lemmens, R. (1999) *Plant Resources of South-East Asia No. 12(1): Medicinal and Poisonous Plants*. Backhuys Publishers.
10. Devi, O.Z., Rao, K.S., Bidalia, A.B.A., Wangkheirakpam, R.W., Singh, O.M. (2015) GC–MS analysis of phytochemicals and antifungal activities of *Zanthoxylum acanthopodium* DC. collected from Manipur, India. *Eur. J. Med. Pharm. Sci.* 4(10), 541–548.
11. Diep, T.T., Dung, L.V., Trung, P.V., Hoai, N.T., Thao, D.T., Uyen, N.T.T., Linh, T.T.H., Ha, T.H.N., Truc, H.T. (2023) Chemical composition and antimicrobial, NO-inhibition and cytotoxic activities of *Zanthoxylum acanthopodium* essential oils. *Chem. Biodivers.* 20(8), e202300649.
12. Elfahmi, W.H., Jamu, K.O. (2014) Indonesian traditional herbal medicine towards rational phytopharmacological use. *J. Herb. Med.* 4(2), 51–73.
13. Fan, Q.F., Zhou, L., Gongpan, P.C., Lu, C.L., Chang, H., Xiang, X. (2023) Bioactivity-guided counter-current chromatography for isolation of anti-inflammatory lignins from *Zanthoxylum acanthopodium* var. *timbor*. *Molecules* 28(6).
14. Farida, Y., Azela, W., Lestari, M.E., Pratami, D.K. (2021) Quality parameters, total flavonoids and antioxidant activity of *Zanthoxylum acanthopodium* fruit extract. *Int. J. Appl. Pharm.* 13(2), 34–40.
15. Frederick, E., Sibero, M., Wijaya, A., Syafitri, E., Siswanto, A.P., Murwani, R., Wijayanti, D., Sabdon, A., Pringgengies, D., Radjasa, O. (2021) Anti-fish pathogenic bacteria activity and metabolite profile of *Zanthoxylum acanthopodium* fruit ethanol extract. *IOP Conf. Ser.: Earth Environ. Sci.* 750, 012026.
16. Gea, S., Pasaribu, K.M., Sarumaha, A.A., Rahayu, S. (2022) Cassava starch/bacterial cellulose-based bioplastics with *Zanthoxylum acanthopodium*. *Biodiversitas* 23(5), 2601–2608.
17. Harahap, U., Hasibuan, P.A.Z., Sitorus, P., Arfian, N., Satria, D. (2018) Antimigration activity of ethyl acetate fraction of *Zanthoxylum acanthopodium* in 4T1 breast cancer cells. *Asian Pac. J. Cancer Prev.* 19(2), 565–569.
18. He, Q., Wang, W., Zhu, L. (2018) Larvicidal activity of *Zanthoxylum acanthopodium* essential oil against *Anopheles anthropophagus* and *A. sinensis*. *Malar. J.* 17(1), 194.
19. Hutapea, D.B., Susilawati, Y., Muhaimin, M., Chaerunisa, A.Y. (2024) Potent bioactivity of andaliman (*Zanthoxylum acanthopodium* DC.). *Pharmacia* 71, 1–10.
20. Ira, S., Ermi, G., Linda, C. (2022) Antioxidant and antibacterial activity of ethanol extract of andaliman fruit (*Zanthoxylum acanthopodium*) using DPPH and MIC methods. *Int. J. Health Pharm.* 2(2), 215–224.
21. Julistiono, H., Lestari, F.G., Iryanto, R., Lotulung, P.D. (2018) Antimycobacterial activity of *Zanthoxylum acanthopodium* fruit against *Mycobacterium smegmatis*. *Avicenna J. Phytomed.* 8(5), 432–438.
22. Lubis, M.F., Hasibuan, P.A., Syahputra, H., Astyka, R. (2022) A review on phytochemicals and pharmacological activities as ethnomedicinal uses of duku (*Lansium domesticum* Corr.). *Open Access Maced. J. Med. Sci.* 10(F), 57–65.
23. Majumder, M., Sharma, H., Zaman, K., Lyngdoh, W. (2014) Evaluation of physicochemical properties and antibacterial activity of essential oil of *Zanthoxylum acanthopodium* DC. from Meghalaya, India. *Int. J. Pharm. Sci.* 6(5), 543–546.
24. Manurung, R.D., Ilyas, S., Hutahaean, S., Rosidah, R., Simanullang, R.H. (2021) Effect of nano-herbal *Zanthoxylum acanthopodium* on VEGF expression in diabetic burn wounds. *IEEE InHeNce Conf.*, 1–5.
25. Megawati, E.R., Bangun, H., Putra, I.B., Rusda, M., Syahrizal, D., Jusuf, N.K., Eyoanor, P.C., Lubis, R.R., Amin, M.M. (2023) FTIR phytochemical analysis of *Zanthoxylum acanthopodium* fruit extracts and fractions. *Med. Arch.* 77(3), 183–188.
26. Muzafri, A., Julianti, E., Rusmarilin, H. (2017) Extraction of antimicrobial components of andaliman (*Zanthoxylum acanthopodium* DC.) and application on catfish (*Pangasius sutchi*) fillet. *IOP Conf. Ser.: Earth Environ. Sci.* 122, 012089.
27. Muzafri, A., Karno, R. (2022) Testing extracts of *Zanthoxylum acanthopodium* with various solvents on the growth of *Escherichia coli*. *KESANS Int. J. Health Sci.* 1(4), 337–343.
28. Napitupulu, F.I., Sulistyani, S., Prangdimurti, E., Wijaya, C.H. (2022) Ethanolic extract of *Zanthoxylum acanthopodium* induces apoptosis in colon cancer cells. *Curr. Res. Nutr. Food Sci.* 10(3), 1046–1057.

29. Ompusunggu, N.P., Irawati, W. (2021) Andaliman (*Zanthoxylum acanthopodium* DC.), a rare endemic plant from North Sumatra rich in essential oils and potentially antioxidant and antibacterial. *J. Biol. Trop.* 21(3), 1063–1072.
30. Panggabean, L., Nurhamidah, N., Handayani, D. (2020) Phytochemical profile and cytotoxicity of ethanol extract of *Zanthoxylum acanthopodium* using BSLT. *Alotrop* 4(1), 59–68.
31. Panjaitan, R., Mahfud, M. (2020) Microwave hydrodistillation of andaliman (*Zanthoxylum acanthopodium* DC) seed essential oil using Box–Behnken design. *IOP Conf. Ser.: Mater. Sci. Eng.* 1053, 012122.
32. Pasaribu, K.M., Gea, S., Ilyas, S., Tamrin, T., Sarumaha, A.A., Sembiring, A., Radecka, I. (2020) Fabrication and in-vivo evaluation of *Zanthoxylum acanthopodium*–loaded bacterial cellulose for burn wound dressing. *Polymers* 12(7), 1436.
33. Pradeep, A., Dinesh, M., Govindaraj, A., Vinothkumar, D., Ramesh Babu, N. (2014) Phytochemical analysis of some important medicinal plants. *Int. J. Biol. Pharm. Res.* 5(1), 48–50.
34. Purba, S.T., Sinaga, D.P. (2017) Immunostimulant potential of *Zanthoxylum acanthopodium* extract in rats. *Pros. Sem. Nas. Biol. Pembelajaran.*
35. R, D.M., Ilyas, S., Hutahaean, S., Rosidah, R., Situmorang, P.C. (2021) Diabetic wound healing in FGF expression by nano herbal of *Rhodomyrtus tomentosa* L. and *Zanthoxylum acanthopodium* fruits. *Pak. J. Biol. Sci.* 24(3), 401–408.
36. Rahmawaty, R., Samosir, J., Batubara, R., Rauf, A. (2019) Diversity and distribution of medicinal plants in the Universitas Sumatera Utara Arboretum of Deli Serdang, North Sumatra, Indonesia. *Biodiversitas* 20(5), 1457–1465.
37. Rahmi, E.P., Makkiyah, F.A., Septama, A.W., Tasfiyati, A.N., Dewi, R.T. (2023) Phytochemical analysis and antioxidant activity of *Zanthoxylum acanthopodium* essential oils. *Matrix Sci. Pharma* 7(1), 22–26.
38. Rapoliene, L., Matuleviciute, V. (2023) Future prospective of herbal medicines for lifestyle diseases. In: Dhara, A.K., Mandal, S.C. (Eds.), *Role of Herbal Medicines*. Springer, Singapore.
39. Rizqoh, D., Sipriyadi, S., Suryani, U.H., Putri, C.N., Agustin, M., Taurustya, H., Lestari, N., Sariyanti, M. (2024) Antibacterial activity of endophytic bacteria from *Zanthoxylum acanthopodium* against *Bacillus subtilis*. *Biodiversitas* 25(2).
40. Rosidah, R., Hasibuan, P.A.Z., Haro, G., Satria, D. (2019) Cytotoxicity of ethanol extract of andaliman fruits toward 4T1 cells. *Indones. J. Pharm. Clin. Res.* 2(2), 31–35.
41. Sangat, H., Zuhud, E., Damayanti, E. (2000) *Kamus Tumbuhan Obat Indonesia (Etnofitomedika I)*. Yayasan Obor Indonesia, Jakarta.
42. Saragih, D.E., Arsita, E.V. (2019) The phytochemical content of *Zanthoxylum acanthopodium* and its potential as a medicinal plant in the regions of Toba Samosir and North Tapanuli, North Sumatra. *Pros. Sem. Nas. Masy. Biodiv. Indon.* 5(1), 71–76.
43. Satria, D., Silalahi, J., Haro, G., Ilyas, S., Hasibuan, P.A.Z. (2019) Cell cycle inhibition by ethyl acetate fraction of *Zanthoxylum acanthopodium* fruit in T47D cells. *Open Access Maced. J. Med. Sci.* 7(5), 726–729.
44. Satria, D., Dalimunthe, A., Pertiwi, D., Muhammad, M., Kaban, V.E., Nasri, N., Waruwu, S.B. (2023) Phytochemicals, proximate, minerals and volatile oils of *Zanthoxylum acanthopodium* fruits. *F1000Research* 12, 221–227.
45. Shylla, A., Pathaw, D., Roy, B. (2022) Toxicological assessment of methanolic fruit extract of *Zanthoxylum acanthopodium* in Swiss albino mice. *Toxicol. Int.* 29(1), 75–93.
46. Siahaan, L., Hilwan, I., Setiawan, Y. (2019) Spatial distribution of andaliman potential habitat (*Zanthoxylum acanthopodium* DC.) in Samosir Island, North Sumatra. *J. Pengelolaan Sumberd. Alam Lingkung.* 9(4), 861–871.
47. Sibero, M.T., Siswanto, A.P., Murwani, R., Frederick, E.H., Wijaya, A.P., Syafitri, E., Farabi, K., Saito, S., Igarashi, Y. (2020) Antibacterial, cytotoxicity and metabolite profiling of crude methanolic extract from andaliman (*Zanthoxylum acanthopodium*) fruit. *Biodiversitas* 21(9).
48. Sihombing, N.S., Sihombing, F., Juwitaningsih, T., Roza, D., Pasaribu, D.M. (2018) Antibacterial activity of *Zanthoxylum acanthopodium* extract on *Bacillus subtilis* and *Salmonella typhi*. In: *AISTSSE Proceedings*, Medan, Indonesia, pp. 221.
49. Sihotang, Y., Satria, D., Silalahi, J., Hadisahputra, S., Hasibuan, P.A.Z. (2016) Cardioprotective effect of ethyl acetate extract of *Zanthoxylum acanthopodium* against doxorubicin toxicity. *Int. J. PharmTech Res.* 9(4), 249–253.
50. Siregar, B. (2003) Andaliman (*Zanthoxylum acanthopodium* DC.) in North Sumatra: Description and germination. *Hayati* 10(1), 38–40.
51. Sitanggang, F.M.C., Duniaji, A.S., Pratiwi, I. (2019) Inhibition of *Escherichia coli* by ethyl acetate extract of *Zanthoxylum acanthopodium* fruit. *J. Ilmu Teknol. Pangan* 8(3), 257–266.
52. Situmorang, P.C. (2020) Acute toxicity and histological effects of nano-herbal *Zanthoxylum acanthopodium*. *Rasayan J. Chem.* 13(2), 780–788.
53. Sonangda, M., Sinaga, H., Limbong, L. (2019) Effect of ratio of andaliman (*Zanthoxylum acanthopodium*) with garlic and aging time on quality of sambal tuk. *IOP Conf. Ser.: Earth Environ. Sci.* 260, 012084.
54. Suryanto, E., Sastrohamidjojo, H., Raharjo, S. (2004) Antiradical activity of andaliman (*Zanthoxylum acanthopodium* DC.) fruit extract. *Indones. Food Nutr. Prog.* 11(1), 15–19.
55. Susanti, N., Situmorang, E., Fitri, W. (2020) Effectiveness of antibacterial activity of n-hexane extract of andaliman (*Zanthoxylum acanthopodium* DC.) against *Bacillus subtilis*, *Salmonella typhi*, and *Staphylococcus aureus*. *J. Phys. Conf. Ser.* 1462, 012072.
56. Syahputra, R.A., Juwita, N.A., Astyka, R., Lubis, M.F. (2023) Andaliman (*Zanthoxylum acanthopodium* DC.), a

- herbal medicine from North Sumatera, Indonesia: Phytochemical and pharmacological review. *Heliyon* 9(5).
57. Syari, D.M., Rosidah, R., Hasibuan, P.A.Z., Haro, G., Satria, D. (2019) Evaluation of cytotoxic activity of alkaloid fractions of *Zanthoxylum acanthopodium* DC. fruits. *Open Access Maced. J. Med. Sci.* 7(22), 3745.
58. Tala, Z.Z., Siregar, G.A. (2022) Effect of *Zanthoxylum acanthopodium* fruit extract on anticancer activity in HepG2 cells. *Open Access Maced. J. Med. Sci.*
59. Thu, H.M., Ngyone, C.H., Hlaing, W.T.Z., Lin, M.T. (2024) Isolation of bioactive compounds from fruits of *Zanthoxylum acanthopodium*. *Myanmar–Korea Conf. Res. J.* 4(2).
60. Wen, J., Xiang, Q., Guo, J., Zhang, J., Yang, N., Huang, Y., Chen, Y., Hu, T., Rao, C. (2024) Pharmacological activities of *Zanthoxylum* L. plants and its exploitation. *Heliyon* 10(12), e33207.
61. Wijaya, C.H., Napitupulu, F.I., Karnady, V., Indariani, S. (2019) A review of the bioactivity and flavor properties of the exotic spice andaliman (*Zanthoxylum acanthopodium* DC.). *Food Rev. Int.* 35(1), 1–19.
62. Xuliang, X., Ginting, J.B. (2022) Analysis of wound healing from andaliman fruit essential oil ointment (*Zanthoxylum acanthopodium* DC.) on Wistar rats (*Rattus norvegicus*). *Brit. Int. Exact Sci. J.* 4(1), 31–42.
63. Yang, J., Song, X., Hu, H., Zhong, W., Cao, R., Xu, Y., Li, R. (2022) Chemical composition and antifungal, anti-inflammatory, antiviral and larvicidal activities of essential oils of *Zanthoxylum acanthopodium* from China and Myanmar. *Molecules* 27(16).